注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
NeuBase Therapeutics Inc是一家临床前阶段生物制药公司。该公司正在开发模块化肽核酸(PNA)反义寡核苷酸(PATrOL)平台,以治疗遗传疾病。PATrOL支持的抗基因疗法旨在通过将合成方法的优势与反义技术的精确性相结合,改进当前的遗传医学策略。其项目包括HD的NT-0100、1型肌强直性营养不良(DM1)的NT-0200和KRAS驱动的癌症的NT-0300。NT-0100程序是一个开发中的PATrOL支持的治疗程序,以靶向HD信使核糖核酸(mRNA)的突变扩增。NT-0200程序是一个开发中的PATrOL支持的治疗程序,以靶向DM1疾病mRNA中的突变扩增。NT-0300程序是一个正在开发中的PATrOL支持的治疗程序,用以靶向突变KRAS基因。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Robert Zamboni | - | - | Chief of Preclinical Development & Member of Scientific Advisory Board |
Dov A. Goldstein | 55 | 2019 | Independent Chairperson |
Eric I. Richman | 62 | 2019 | Independent Director |
Robert Friedlander | - | - | Chair of Scientific Advisory Board |
George McDonald Church | 69 | 2023 | Chairperson of Gene Editing Advisory Board & Member of Scientific Advisory Board |
Peter Nielsen | - | 2020 | Member of Gene Editing & Scientific Advisory Board |
Randy Davis | - | 2020 | Member of Scientific Advisory Board |
Eriks Rozners | - | 2020 | Member of Gene Editing & Scientific Advisory Board |
Gerald J. Mcdougall | 56 | 2021 | Independent Director |
Danith H. Ly | - | 2019 | Member of Advisory Board |
Steven F. Dowdy | - | 2019 | Member of Gene Editing & Scientific Advisory Board |
James M. Coull | - | 2023 | Member of Gene Editing Advisory Board |
Jeremy Stark | - | 2023 | Member of Gene Editing Advisory Board |
Dietrich A. Stephan | 54 | 2019 | Founder, President & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核